Itch is a distinct aversive sensation that elicits a strong urge to scratch. Despite recent advances in our understanding of the peripheral basis of itch, we know very little regarding how central neural circuits modulate acute and chronic itch processing. Here we establish the causal contributions of defined periaqueductal gray (PAG) neuronal populations in itch modulation.
Introduction
Itch is a distinct unpleasant sensation that evokes a strong desire to scratch 1 . While acute itch is posited to play an important physiological role as a defense mechanism, chronic itch disorders are disabling and often difficult to treat. Chronic itch (pruritus) disorders affect 15% of the population are often associated with neuropathy, skin disease, and organ dysfunction and are the most frequent cause of visits to dermatologists 2 . Antihistamines are the first-line treatment for itch, but fail to control most forms of chronic pruritus 2 . Recently, non-histaminergic pathways for itch have been identified. Effective alternative therapies that target non-histaminergic pathways
are not yet available [3] [4] [5] .
The neural pathways that signal itch and pain appear remarkably similar, and significant advances have recently been made to tease apart itch and pain circuitry at the level of the primary afferent fibers and the spinal cord [3] [4] [5] . However, whether itch and pain information are integrated into the same or different neuronal populations is currently a matter of controversy. In agreement with the concept of shared processing nodes, recent studies support the notion of a robust itch modulatory system within regions of the nervous system that are related to nociception [6] [7] [8] [9] [10] [11] [12] [13] . For example, scratching the skin reduces the firing rate of primate spinothalamic tract (STT) neurons responding to pruritogens, but does not alter neuronal responses to painful stimuli 14 . In addition, inhibition or transection of the upper cervical spinal cord reduces scratch-evoked inhibition of spinal cord neuronal activity induced by pruritic stimuli, suggesting that the inhibitory effect of scratching is due to the engagement of a strong descending supraspinal influence on spinal itch processing 15 . The nature of this supraspinal itch modulatory system is not known, but the similarities in anatomical pathways for pain and itch provide a framework for testable hypotheses.
Neuroimaging studies suggest that the periaqueductal gray, an evolutionarily conserved structure in the midbrain, may mediate the suppression of itch induced by noxious counter-stimuli such as cold and scratching [16] [17] [18] . The ventrolateral periaqueductal gray (vlPAG) has been shown to regulate several complex behaviors including pain 19 and is a major site of endogenous opioidinduced pain suppression 20 . Electrical stimulation of the PAG produces profound analgesia 21, 22 by modulating spinal nociceptive transmission in part by descending projections to the rostral ventromedial medulla (RVM), which sequentially projects to the spinal cord [23] [24] [25] [26] . It has been demonstrated in cats that 27 the magnitude of the response to a pruritic stimulus is greatly diminished following decerebration, suggesting the existence of a descending itch modulation system. Consistent with this idea, electrical stimulation of the PAG results in inhibition of spinal neurons responsive to intracutaneous delivery of histamine 28 , and this inhibition is lost upon termination of PAG stimulation,. Although the importance of the PAG in pruritic modulation is established, very little is known regarding how the PAG participates in pruritic processing. An understanding of the midbrain neural circuits and transmitters that underlie the suppression of itch may identify novel targets for the treatment of pruritus, in a manner similar to the advancement of opioid receptor pharmacology from our understanding of the role of the PAG in pain modulation [29] [30] [31] [32] .
Here, we use pharmacological, cell type-specific chemogenetic manipulations and optical imaging approaches to functionally identify and dissect the involvement of specific PAG neuronal subpopulations in the modulation of acute and chronic itch. The results that follow highlight the bidirectional modulation of scratching behaviors by PAG neurons, with opposing roles of glutamatergic and GABAergic subpopulations in mediating the sensory component of itch.
Further, we identify a unique role for GABAergic PAG neurons in the encoding or modulation of itch-related aversion.
Results

Manipulation of vlPAG activity suggests bidirectional modulation of itch-related behaviors
To determine the overall contribution of the vlPAG to itch processing, we performed bilateral microinjection of 4 % lidocaine (a short acting Na + channel blocker) into the vlPAG to block neuronal activity during pruritogen-induced scratching. Bilateral lidocaine microinjection into the vlPAG significantly attenuated scratching evoked by intradermal injection of the nonhistaminergic pruritogen chloroquine (200ug/50ul) (Figure 1a , e, f). Vehicle microinjection into the vlPAG did not produce any changes in chloroquine evoked scratching (Figure 1d , f).
While this result suggests the importance of the vlPAG in regulating pruritogen-evoked scratching, the nature of lidocaine action raises the question of whether resident neurons within the vlPAG or fibers of passage within the vlPAG contribute to itch processing. We therefore turned to a chemogenetic approach to selectively activate or inhibit resident vlPAG neurons. Adeno-Associated Virus type 8 (AAV8) vectors carrying neuron-specific stimulatory (hM3Dq) or inhibitory (hM4Di) DREADDs fused with mCherry (AAV8-hSyn-hM3Dq/hM4Di-mCherry) 33 were microinjected bilaterally into the vlPAG (Figure 2a , 2e). In animals expressing the stimulatory DREAAD (hM3Dq), clozapine-N-oxide (CNO) injection (1 mg/kg, i.p) resulted in a significant reduction in chloroquine evoked scratching (Figure 2b , 2c,). This reduction was dose dependent ( Figure S1a ). As a control, and to rule out any possibility of CNO having any effect on chloroquine evoked scratching, we administered CNO to mice injected with an EGFP control virus (AAV8-hSyn-eGFP) and observed no significant effect on chloroquine-evoked scratching behavior.
Reduction in chloroquine evoked scratching in hM3Dq-injected mice after CNO administration significantly correlated with the number of hM3Dq-mCherry + vlPAG neurons. (R 2 = 0.66, P = 0.0001, Figure 2d ). In contrast, CNO (1 mg/kg, i.p) administration in mice expressing the inhibitory DREAAD (hM4Di) in the vlPAG, resulted in a significant increase in chloroquine evoked scratching (Figure 2f, 2g ), compared to mice expressing the control EGFP vector in the vlPAG.
The CNO-mediated increase in chloroquine-evoked scratching in mice expressing the inhibitory DREAAD (hM4Di) in the vlPAG was dose-dependent ( Figure S1b ). Again, this increase in chloroquine-evoked scratching in hM4Di-injected mice after CNO administration demonstrated a significant correlation with the number of hM4Di-mCherry + vlPAG neurons. (R 2 = 0.38, P = 0.01, Figure 2h ). This result showing that targeted inhibition of resident vlPAG neurons results in increased scratching is in stark contrast to the results from the lidocaine experiment described above, where inactivation of vlPAG (including both resident neurons and fibers of passage) led to reduced scratching. Taken together, these findings illustrate the importance of using cell-specific 6 approaches, and demonstrate that activating vlPAG neurons attenuates pruritus, while inhibiting vlPAG neurons potentiates pruritic behaviors.
Pruritogen-induced conditioned place aversion is blocked by chemogenetic activation of vlPAG neurons
Itch is an unpleasant emotional experience in humans. We adapted a conditioned place aversion (CPA) paradigm to evaluate the unpleasant affective component of itch in mice ( Figure   S2a ). We hypothesized that chloroquine-induced itch would produce negative reinforcement.
Mice were given free access to all chambers on day one. The mice were then paired with saline injection or chloroquine injection in separate chambers distinguishable by vertical or horizontal stripes for three subsequent days. Twenty-four hours after the last pairing, mice were given free access to both chambers and the time spent in each chamber was recorded. Consistent with our hypothesis, mice exhibited robust aversion to the chamber paired with chloroquine injection compared to the chamber paired with saline injection ( Figure S2b & c). CPA to chloroquine was dose dependent; 50µg/10µl chloroquine did not show CPA while doses of 200µg and 400µg/10µl produced significant CPA ( Figure S2c ). All groups spent an equivalent time in the neutral chamber (data not shown). These results suggest that chloroquine produces reliable, robust place aversion, consistent with a recent report 34 .
Having demonstrated that chemogenetic activation of vlPAG neurons suppresses chloroquine-induced scratching, we next asked whether chemogenetic activation of vlPAG neurons would abolish place aversion to chloroquine. We transduced vlPAG neurons bilaterally with AAV8 vectors carrying either the stimulatory DREADD (hM3Dq) fused with mCherry or control AAV8 EGFP. After free access to both chambers on day 1, mice were conditioned for 3 days, by administering either saline or chloroquine. On conditioning days, mice were pre-treated with either saline or CNO (i.p) 1h before being paired in the specified chambers with saline or chloroquine injection ( Figure 2i 
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The results above show that excitation of vlPAG neurons leads to suppression of chloroquine-evoked scratching, whereas inhibition of vlPAG neuronal activity potentiates chloroquine-evoked scratching. However, the vlPAG is composed of both inhibitory GABAergic and excitatory glutamatergic neurons, which are non-overlapping populations [35] [36] [37] . The chemogenetic manipulations of vlPAG neuronal activity in the prior experiments do not distinguish between these two populations. To investigate the potential for differential roles of vlPAG GABAergic and glutamatergic neurons in the regulation of itch behaviors, we used fiber photometry 38 to measure bulk Ca 2+ dynamics in a cell type-specific manner in awake, behaving At the onset of grooming or wiping, Ca 2+ dynamics were variable but not significantly changed, suggesting that the fluorescence changes described above are functionally related to chloroquineinduced scratching (Figure 3i & k). To further verify that changes observed in Vgat+ and Vglut2+ vlPAG neurons are correlated with chloroquine-evoked scratching behaviors, we generated randomly assigned arbitrary bout events and aligned Ca 2+ transients to these arbitrary bouts. Ca 2+ dynamics of Vgat+ and Vglut2+ vlPAG neurons were not significantly correlated with these arbitrarily created bouts (Figure 3j & l). Altogether these data suggest that vlPAG Vgat + and Vglut2 + neurons respond differently during chloroquine-evoked scratching. Our results capture the rapid changes in activity that these neurons undergo in response to chloroquine-evoked scratching and suggest that a cell type-specific approach is needed to understand the role of vlPAG neurons in sensory and affective aspects of itch.
Chemogenetic manipulation of vlPAG GABAergic neuron activity modulates acute and chronic scratching behaviors
The fiber photometry studies described above show a decrease in activity of Vgat + neurons during chloroquine-evoked scratching, suggesting a potential role for reduced GABAergic transmission in the vlPAG in itch processing. To test the hypothesis that altered vlPAG To investigate whether activation of vlPAG GABAergic neurons can attenuate chronic itch, we used a dry skin model of itch. Chronic spontaneous scratching develops following daily topical application of acetone/ether/water (AEW) for 7 days [39] [40] [41] . Seven days after AEW treatment, Vgat::mCh-and Vgat::hM3Dq-injected mice showed robust spontaneous scratching. On day 8, chemogenetic activation of vlPAG GABAergic neurons with CNO (5 mg/kg, i.p.) resulted in a significant reduction of spontaneous scratching behavior produced by AEW treatment (Figure 4h ).
In Vgat::mCherry mice, CNO administration did not affect spontaneous scratching behavior produced by AEW treatment.
We next tested whether chemogenetic activation of vlPAG GABAergic neurons would block the aversive component of chloroquine-induced itch. We performed CPA to chloroquine in Vgat::hM3Dq and Vgat::mCherry mice. During conditioning, mice were pre-treated with either saline or CNO (i.p) 1h before being placed in the saline or chloroquine paired chamber ( Figure   4I ). When allowed free access to both chambers following conditioning, Vgat::hM3Dq-injected mice spent similar time in both chambers whereas Vgat::mCherry-injected controls spent significantly less time in the chamber that was paired with chloroquine (4j, k, l & m). Neither Vgat::hM3Dq nor Vgat::mCherry showed any change in chamber preference from their initial exploration. Neither group showed altered locomotor activity following CNO administration.
These results demonstrate that activation of vlPAG GABAergic neurons attenuates place aversion to chloroquine and suggest that these neurons modulate the aversive component of itch.
Chemogenetic manipulation of vlPAG glutamatergic neuron activity modulates acute and chronic itch behaviors
The increases in vlPAG Vglut2 + neuronal activity observed during scratching (fiber photometry recordings above) suggest a potential causal relationship between activity of these neurons and chloroquine-evoked scratching behaviors (Figure 3f , g &h). To test this hypothesis, we expressed Cre-dependent hM3Dq-mCherry or a control virus lacking the DREADD (Syn-mCh) selectively in glutamatergic (Vglut2-expressing) vlPAG neurons ( Figure 5a ) and asked if increasing the activity of Vglut2 neurons could augment chloroquine-evoked scratching behavior.
It is important to note that we recently demonstrated that CNO reliably modulates the activity of vlPAG glutamatergic neurons expressing DREADDs 36 . Three weeks after DREADD injection, robust viral expression was observed in the vlPAG (Figure 5a ). Activation of vlPAG Vglut2::hM3Dq neurons via CNO (5 mg/kg, i.p.) led to a profound increase in chloroquine-evoked scratching compared to baseline (Figure 5b , c). CNO administration in Vglut2::mCherry mice had no effect on chloroquine-evoked scratching, indicating that elevated glutamatergic activity in the vlPAG is sufficient to enhance chloroquine-evoked scratching. The increase in chloroquine evoked scratching in hM3Dq-injected mice after CNO administration is dose dependent ( Figure  S1e ) and significantly correlated with the number of hM3Dq-mCherry + vlPAG neurons (R 2 = 0.39, P = 0.01, Figure 5d ).
Next, we assessed whether endogenous activity of vlPAG Vglut2 neurons is necessary for regulating itch processing. Inhibition of Vglut2+ vlPAG neurons in Vglut2::hM4Di mice with CNO (5 mg/kg; i.p) resulted in a significant decrease in chloroquine-evoked scratching compared to baseline (Figure 5e , f). The CNO-mediated decrease in chloroquine-evoked scratching is dose dependent ( Figure S1f ). Mice expressing the control mCherry vector in vlPAG glutamatergic neurons show no significant change in scratching behavior upon CNO administration. These decreases also significantly correlate with the number of hM4Di-mCherry + vlPAG neurons in Vglut2 Cre mice. (R 2 = 0.45, P = 0.005, Figure 5g ).
We further analyzed whether inhibition of vlPAG glutamatergic neurons can affect scratching behaviors in the AEW dry skin model of chronic itch. Vglut2::mCh-and Vglut2::hM4Diinjected mice showed robust spontaneous scratching seven days after AEW treatment.
Chemogenetic inhibition of vlPAG glutamatergic neurons (Vglut2::hM4Di) with CNO (5 mg/kg, i.p.) resulted in a significant reduction of spontaneous scratching behavior produced by dry skin (Figure 5h ). CNO administration in Vglut2::mCherry mice did not lead to changes in spontaneous scratching behavior produced by dry skin. These results demonstrate that activity of vlPAG glutamatergic neurons is necessary for acute and chronic itch processing.
To determine if chemogenetic inhibition of vlPAG glutamatergic neurons can block the aversive component of chloroquine-induced itch, we performed CPA to chloroquine in Vglut2::hM4Di and Vglut2::mCherry mice ( Figure 5i ). In contrast to what we observed following modulation of vlPAG GABAergic neurons, modulation of the activity of glutamatergic vlPAG neurons had no effect on place aversion induced by chloroquine. Thus, when allowed free access to both chambers following conditioning, both Vglut2::hM3Dq and Vglut2::mCherry injected mice spent significantly less time in the chloroquine-paired chamber, suggesting that place aversion was not suppressed by activation of vlPAG glutamatergic neurons. Neither Vglut2::hM3Dq ( Figure   5k , p) nor Vglut2::mCherry mice (Figure 5j , l) showed any change in behavior from their initial exploration and neither group showed altered locomotor activity following CNO administration.
These results demonstrate that inhibition of vlPAG glutamatergic neurons did not prevent place aversion to chloroquine and suggest that vlPAG glutamatergic neurons do not contribute to the aversive component of itch.
Discussion
More than 70 years ago, the brainstem was shown to play a crucial role in itch modulation 27 . Recent studies have acknowledged the presence of defined neural circuits underlying itch processing in the brainstem, supporting this hypothesis 11, 12, 42 . It has been demonstrated that electrical stimulation of the PAG suppresses responsiveness of spinal cord neurons to histamine 28 , but the neural subtypes involved in modulating itch processing have never been identified. Our initial experiment to test for a role of the vlPAG in itch processing in mice utilized local pharmacologic blockade of neuronal activity (lidocaine), and supported the above studies suggesting a role for the PAG in itch modulation. This approach lacks cell-type specificity, and additionally inhibits axons coursing through our nearby the injections site. Our findings using global (not cell-type-specific) DREADD manipulation of vlPAG neurons demonstrate that activation of vlPAG neurons results in robust suppression of chloroquine-evoked scratching, while inhibition of vlPAG neurons results in profound potentiation of chloroquine-evoked scratching.
This approach eliminated the possible stimulation or inhibition of axons coursing through the PAG that confounds studies utilizing either electrical stimulation-induced activation or silencing via cooling or local anesthetic administration. However, the experiments that followed demonstrate diverse roles for different cell types in the vlPAG, in a manner not easily predicted from global electrical, pharmacologic, or chemogenetic approaches described here and previously.
The PAG comprises a diverse group of neuronal subpopulations that express a variety of neurotransmitters and neuropeptides in a mosaic manner [43] [44] [45] . It is unclear how distinct neuronal populations integrate and modulate different sensations. We and others have shown that the vlPAG GABAergic and glutamatergic neurons differentially modulate pain neurotransmission 29, 30, [35] [36] [37] [46] [47] [48] [49] [50] . Itch and pain exhibit a reciprocal relationship at the behavioral level. For example, itch is suppressed by the mild noxious mechanical stimulus of scratching 14, 17, 18, 51 . Given this inverse relationship of itch and pain and these identified differential roles for these neuronal populations in the vlPAG, we investigated the role of GABAergic and glutamatergic vlPAG neurons in the processing of itch. We observed that vlPAG GABAergic and glutamatergic neurons exhibited opposing effects on pruritic information processing. Activation of vlPAG GABAergic The opposing and unique actions of glutamatergic and GABAergic neurons in the modulation of itch identified here emphasize the importance of using cell-type-specific approaches. This also suggests that further dissection of these neuronal subtypes should be undertaken. We have chosen to assess potential unique roles for glutamatergic and GABAergic neurons for the reasons mentioned above, however the PAG comprises multiple neuronal populations expressing several neurotransmitters and neuropeptides [43] [44] [45] . Even among the subpopulations studied here, there are certain to be further subclassifications based on anatomy (e.g. projection targets, source of synaptic inputs) or neurochemistry (e.g. neuropeptides or other co-expressed neuromodulators). It is unlikely that all the GABAergic and glutamatergic vlPAG neurons show the same response to pruritic processing. Future studies may discover additional heterogeneity in GABAergic and glutamatergic neuronal subtypes based on their gene expression and their anatomical downstream targets.
The PAG forms strong connections with the amygdala, the habenula, several thalamic and hypothalamic nuclei, the RVM and the locus coeruleus 24, 46, 50, [54] [55] [56] [57] [58] . In future studies, it will be of great interest to determine which of these projection targets, or others, might mediate the differential modulation of pain and itch from glutamatergic and GABAergic projections from the vlPAG. The balance of activity in the vlPAG might lead to differential modulation of the activity in downstream projection targets and contribute to the inverse control of pain and itch processing in the spinal cord.
Since itch, like pain, is an aversive sensory experience in humans 17, 18, 51, 59, 60 , we hypothesized that pruritogen-evoked itch would produce an aversive state in mice. Here we demonstrate that itch evoked by chloroquine administration resulted in robust conditioned place aversion, in a dose-dependent manner demonstrating that in mice itch is fundamentally an aversive sensation, consistent with recent studies 34 . We also demonstrated that activation of vlPAG neurons abolishes CPA to chloroquine. Furthermore, activation of vlPAG GABAergic neurons prevented place aversion to chloroquine suggesting that vlPAG GABAergic neurons encode the aversive component of itch. Surprisingly, inhibition of vlPAG glutamatergic neurons did not prevent place aversion to chloroquine, though chemogenetic inhibition of these neurons 58, 61, 62 . Recent studies have also shown that VTA dopaminergic neurons are involved in the motivational aspect of itch-evoked scratching 63 . Our results suggest that blockade of CPA could be due to a reduction in the negative affect associated with chloroquine-evoked scratching, or to suppression of transmission of sensory information in itchspecific sensory pathways. Interestingly, recent work using chemogenetic inhibition of vPAG GABAergic neurons suggested that these neurons encode for aversive anxious behaviors 64 .
Together, our data demonstrate that chloroquine-induced itch is a fundamentally aversive sensation and can be suppressed by activating vlPAG GABAergic neurons. We conclude that the vlPAG is a hub that can bidirectionally modulate itch processing in the context of acute and chronic itch. This differential modulation of itch by glutamatergic and GABAergic vlPAG neurons is reciprocal in nature to the role of these same cell populations in the modulation of pain 36 . Our results showing that activation of vlPAG GABAergic neurons or inhibition of vlPAG glutamatergic neurons can attenuate chronic itch suggesting that disengagement in this circuit has the potential to contribute to exacerbation of chronic itch.
The vlPAG is well-positioned to be modulated by top-down control from neural regions important for processing pain and itch 1, 9, 17, 18, 24, 29, 51, 65 , including the somatosensory, anterior cingulate, and insular cortices, as well as the thalamus 66, 67 . The vlPAG has been shown to be instrumental in descending modulation of pain processing 20, 37 . Our current observations identify a previously unknown role of the vlPAG in modulation of itch wherein selective activation and inhibition of specific subsets of vlPAG GABAergic or glutamatergic neurons produces distinct phenotypes. These findings point to the essential role of descending supraspinal circuitry in modulating itch processing, and also support previous studies suggesting the likely existence of strong descending itch modulation pathways 14, 15 . Finally, the unexpected differences observed between global pharmacologic inhibition, global modulation of resident neuronal activity and celltype-selective modulation illustrate the importance of the cell-type-specific approach, and provide a clear case for their use in reexamination of basic tenets of neural circuitry.
Methods
Animals
All experiments were conducted in accordance with the National Institute of Health guidelines and with approval from the Animal Care and Use Committee of Washington University School of Medicine. Mice were housed on a 12-hour light-dark cycle (6:00am to 6:00pm) and were allowed free access to food and water. All animals were bred onto C57BL/6J background and no more than 5 animals were housed per cage. Male littermates between 8-12 weeks old were used for experiments. Slc32a1 tm2Lowl (Vgat-ires-Cre), Slc17a6 tm2Lowl (Vglut2-ires-Cre), and C57BL\6J mice were purchased from Jackson Laboratories and colonies were established in our facilities. Litters and animals were randomized at the time of assigning experimental conditions for the whole study. Experimenters were blind to treatment and genotype.
Viral constructs
Purified and concentrated adeno-associated viruses coding for Cre-independent hM3Dq-mCherry (rAAV8/hSyn-hM3Dq-mCherry; 3.2 x 10 12 particles/ml, Lot number: AV5359 and Lot date: aliquoted and stored in -80°C until use. We functionally verified and validated DREADD constructs we used in this study in our prior publication 36 .
Stereotaxic Surgeries
Mice were anesthetized with 1.5 to 2.0% isoflurane in a gas chamber using isoflurane/breathing air mix. Once deeply anesthetized, they were placed and secured in a stereotactic frame (David Kopf Instruments, Tujunga, CA) where surgical anesthesia was maintained using 2% isoflurane.
Mice were kept on a heating pad for the duration of the procedure. Preoperative care included application of sterile eye ointment for lubrication, administration of 1mL of subcutaneous saline and surgery site sterilization with iodine solution. A small midline dorsal incision was performed to expose the skull and viral injections were performed using the following coordinates: vlPAG, -4.8 to 4.9 mm from bregma, +/-0.3 to 0.4 mm lateral from midline and 2.7 to 2.9mm ventral to skull. Viruses were delivered bilaterally, using a stereotaxic mounted syringe pump (Micro4 Microsyringe Pump Controller from World Precision Instruments) and a custom 2.0uL Hamilton syringe. Injections of 150nL of the desired viral vectors into the area of interest were performed at a rate of 1uL per 10 minutes. We allowed for a 10-minute period post injection for bolus diffusion before removing the injection needle. Postoperative care included closure of the cranial incision with sutures and using veterinary tissue adhesive and application of topical triple antibiotic near the incision site. Animals were monitored while on a heating pad until they full recovery from the anesthetic.
Cannula Implantation and lidocaine infusion
The surgical protocol was the same as the described above for viral injections. Stainless steel guide cannulas (8mm) were implanted at the vlPAG and fixed to the skull using two bone screws (CMA anchor screws, #7431021) and dental cement. An 8mm stylet was used to avoid guide cannula clogging. Mice were allowed to recover for 7 days. Microinjections of 0.25μl 4% lidocaine (Sigma, L1663) diluted in 0.9% saline were performed 15 minutes before pruritic agent induced scratching behavior was assessed. Mice were later euthanized, and cannula placements were verified using cresyl violet nissl stain. Animals in which cannula's were not placed in the vlPAG are excluded from the study.
Chemogenetic manipulation
For non-specific chemogenetic control of vlPAG neurons, C57BL/6J mice were injected with non-Cre dependent control eGFP, hM3Dq or hM4Di viruses. For subpopulation specific chemogenetic control of vlPAG neurons Vgat-ires-Cre and Vglut2-ires-Cre mice were injected with Cre dependent control mCh, hm3Di or hm4Dq viruses. DREADD constructs used in this study were validated previously for their functional expression in the PAG, including their ability to increase (hM3Dq) or decrease (hM4Di) neuronal firing in slices from animals expressing these viral constructs 36 . Three weeks later mice were injected with (C57BL/6J, VGlut2 Cre and VGAT Cre respectively) clozapine N-oxide (CNO, BML-NS105 from Enzo life sciences) 2 hrs before doing behavioral experiments and data were collected between the second-and third-hour postinjection. All baselines for pruritic responses were recorded 2 weeks after the virus injections and one week prior to the CNO administration. We performed dose response studies of CNO to determine the optimal dose for use in behavioral experiments. Based on these dose-finding studies, we selected 5 mg/kg CNO as a dose of CNO that produces near maximal effects in Cre dependent DREADD-expressing animals and showed no signs of behavioral affects in control vector-expressing animals. For non-Cre dependent studies, we observed that a dose above 1 mg/kg CNO was lethal, so we used 1 mg/kg CNO dose for both activation and inhibition of vlPAG neurons.
Pruritic agent induced scratching behaviors
As previously described by our group 41, 68 , the nape of the neck mice was shaved one day prior to experiments. Mice then were placed in clear plexiglass behavioral boxes for at least two hours for acclimation for baselines. For chemogenetic manipulations, CNO was administered before placing the mice in the plexiglass behavioral boxes and chloroquine (200µg/50µl, nape of the neck) induced scratching behavior was performed 90 min after the CNO administration.
Acetone and ether, water (AEW) induced itch
To model dry skin-mediated itch, spontaneous scratching behavior was induced by treatment twice daily with an acetone/diethylether (1:1) solution for 15 seconds followed by water for 30 seconds on the nape of the neck. Following seven days of AEW treatment, spontaneous behavior was video recorded for two hour pre-and post-CNO. Scratch bouts directed to the nape of the neck and rostral back were counted in five-minute intervals during blinded off-line analysis.
Conditioned place aversion (CPA)
CPA was performed using an unbiased, counterbalanced three-compartment conditioning apparatus as described 69 . Each chamber had a unique combination of visual, properties (one side had black and white vertical walls, whereas the other side had black and white striped walls).
On the pre-conditioning day (day 1), mice were allowed free access to all three chambers for To test the effect of DREADD hM3Dq activation on chloroquine-induced place aversion, mice injected with AAV8 hM3Dq-mCherry and AAV8 EGFP were allowed free access to all three chambers for 30 min on the pre-conditioning day (day 1). On day 2, 3 & 4, both mice cohorts received a saline injection (50µl) on the nape of the neck and on the mouse caudal back, and this chamber is paired with systemic saline injection 2 h before they were placed in the compartment in the morning and a chloroquine injection (400µg/50µl) on the nape of the neck and on the mouse caudal back and this chamber is paired with systemic CNO injection 2 h before they were placed in the compartment in the afternoon. To test the effect of DREADD hM3Dq activation on chloroquine-induced place aversion, the mice were allowed free access to the three compartments on day 5 for 30 minutes. Scores were calculated by subtracting the time spent in the chloroquine-paired compartment, post-test minus the pre-test.
Fiber Photometry
For in vivo calcium imaging of vlPAG GABAergic and glutamatergic neurons, we injected vlPAG with Cre-dependent GCaMP6s (AAV-DJ EF1a-DIO-GCaMP6s, 3 x 10 13 particles/ml, Stanford vector core). Fiber optic probes were unilaterally implanted above the left vlPAG ( -4.8 A fiber optic patch cord was used to connect to the fiber implant and deliver light to excite and record the GCAMP signal using a custom-built fiber photometry rig. The fiber photometry recording setup was built with some modifications to previously described specifications 38 . Doric lenses) and sent to a photoreceiver to detect the signal (Newport, 2151). The signal from the photoreceiver was recorded using a RZ5P real-time processor (TDT). Data were acquired at 10 kHz and then demodulated at 211 and 537 Hz. The demodulated signal was then low-pass filtered (4 Hz) in a custom MATLAB script. The extracted 405 nm signal was then scaled to fit the GCaMP signal for the recording session. To isolate the movement-corrected GCaMP signal from channel, we subtracted the signal at 405 nm from the 475 nm GCaMP signal. dF/F was obtained by dividing the final signal with its mean value. Behavioral event timestamps associated with chloroquine evoked scratching behavior were scored and aligned with GCAMP signal in the MATLAB script to create pre-and peri-stimulus time bins. To obtain pre-and peri-stimulus chloroquine evoked scratching events, if the scratching events happened to close to each other in a 30 second window, they we combined and called as one event. Z-score was obtained by subtracting the mean of the GCaMP signal from the bin value of the GCaMP signal and dividing it with the standard deviation of the bin value of the GCaMP signal.
Immunohistochemistry
Adult mice were deeply anesthetized using a ketamine/xylazine cocktail and then perfused with 20ml of with phosphate-buffered saline (PBS) and 4% paraformaldehyde (weight/volume) in PBS (PFA; 4 °C). Brains were carefully removed, post fixed in 4% PFA overnight and later immersed in 30% sucrose for at least 48 hrs. Tissues were mounted in OCT while allowing solidification of the mounting medium at -80 °C. Using a cryostat, 30μm tissue sections were collected and stored in PBS1x 0.4% sodium azide at 4 °C. After washing the sections in PBS1x, we blocked using 5% normal goat serum and 0.2% Triton-X PBS 1x for one hour at room temperature. Primary antibodies against mCherry (Mouse, Clontech, 632543; 1/500) and GFP (rabbit polyclonal anti-GFP, Aves A11122; 1/500) were diluted in blocking solution and incubated overnight at 4 °C. After three 10-minute washes in PBS1x, tissues were incubated for one hour at room temperature with secondary antibodies (Life Technologies: Alexa Fluor488 donkey anti rabbit IgG (1/300); Alexa Fluor 488 goat anti rabbit (1/300); Alexa Fluor 555 goat anti mouse (1/300)) and Neurotrace (435/455nm, 1/500) at room temperature. Three PBS1x washes followed before sections were mounted with Vectashield (H-1400) hard mounting media and imaged after slides cured. Images were obtained on a Nikon Eclipse 80i epifluorescence microscope.
Statistics
Throughout the study, researchers were blinded to all experimental conditions. Exclusion criteria for our study consisted on a failure to localize expression in our experimental models or off-site administration of virus or drug. At least 3 replicates measurements were performed and averaged in all behavioral assays. The number of animals used is indicated by the "N" in each experiment.
When paired t Test was used for comparing paired observations, we evaluated for normality using the D'Agostino and Pearson omnibus normality test for all datasets. Therefore, only when normality could be assumed, we used a parametric test to analyze out data. If normality could not be assumed, a nonparametric test or a Wilcoxon matched pairs text was used to evaluate differences between the means of our experimental groups. Two-way ANOVA was used for comparing between different control and treatment groups. Bonferroni's post hoc tests were used (when significant main effects were found) to compare effects of variables. A value of p <0.05 was considered statistically significant for all statistical comparisons. mg/Kg, P = 0.021, ***1 vs 5, P <0.0001, #2 vs 3, P = 0.0082, ##2 vs 5, P <0.0001; N = 8 for 1 mg/kg, N = 10 for 2 mg/kg, N = 9 for 3 mg/kg and N = 8 for 5 mg/kg). (E) CNO activation of vlPAG Vglut2::hM3Dq neurons produced dose dependent increase in chloroquine evoked scratching (one-way ANOVA, 1 vs 5 mg/Kg, **P = 0.0059, 1.5 vs 5, *P = 0.0210; N = 7 for 1 mg/kg, N = 7 for 1.5 mg/kg, N = 10 for 2 mg/kg and N = 12 for 5 mg/kg). (F) CNO activation of vlPAG Vglut2::hM4Di neurons produced dose dependent decrease in chloroquine evoked scratching (one-way ANOVA, 1 vs 5 mg/Kg, **P = 0.0005, 1.5 vs 5, ***P <0.0001, 2 vs 5, ##P = 0.0011; N = 8 for 1 mg/kg, N = 6 for 1.5 mg/kg, N = 14 for 2 mg/kg and N = 13 for 5 mg/kg). All values are mean ± SEM. 
